Ivan Arnaud

@marianarentj ¿Acaso es porque no estás supportando?

Necesito un supportan

@ProjectImg STUDY

@ProjectImg Does this apply to people who already pay for membership but don’t currently have access to the QBank?

Shoutout to the person who sorted my cells and drew a happy face on the tubes ☺️

The irony of getting a UWorld question about perfectionism interfering with task completion while struggling with perfectionism interfering with UWorld review is pretty perfect 😵‍💫

Duloxetine did not show superiority over placebo in preventing oxaliplatin-induced neuropathy. ascopubs.org/doi/10.1200/OA…

The more we pressure young academics to publish rather than to learn, the more humanity's scientific progress will suffer. youtube.com/watch?v=SEwiOy…

Don’t lie. People will notice, and it’ll make you seem bad.

My heart right now because all of my friends matched!

📊 @AmericanCancer #ColorectalCancer Report 2026: • Incidence ⬆️ 3%/yr in adults 20–49 • Rectal cancers ⬆️, now 32% of all #CRC cases • Mortality ⬇️ 2.3%/yr in adults 65+ 🔸 Rebecca L. Siegel, MPH | @CACancerJournal 🔗 ascopost.com/news/march-202…

But then I tell myself “you chose this” 🤷🏻‍♂️

@AnKingMed Which 3 AMBOSS cards were they?? 😭😭😭

Last minute prep: Relax, read a few AMBOSS cards. Trust the process, don't overthink it.

Well... Can't say I'm not disappointed 😪 "LD is not a safe alternative to ND in HSCT patients and patients with AL because of increased infection risk without nutritional or other benefit." ascopubs.org/doi/10.1200/JC…

@marianarentj Por un momento pensé que esto fue al mismo tiempo que nuestro chat y ya estaba yendo por mis Kleenex para iorar 😭

Tómalo de quien viene

Presented at #ASH25: In untreated chronic lymphocytic leukemia, fixed-duration venetoclax-based regimens were noninferior to continuous ibrutinib with regard to 3-year progression-free survival and were associated with higher MRD-negative rates. Full CLL17 phase 3 trial results: nej.md/3KiZKwl @ASH_hematology

The FOMO is very strong today! 😣#ASH2025 mdanderson.org/cancerwise/4-n…

GIMEMA Ph+ ALL: Blina + Ponatinib in a RCT fashion - new standard of care #ASH25

Friendsgiving dinner was so good we ate everything before taking the group picture. 😅 I’m thankful for moments like these. 💛

We are even recognizing that MRD is also becoming important in solid tumor oncology!

@RocioCasRiv Jaja y el domingo fue igual

@IvanArnaud Que raro es tu sábado

Saturday hood room reflections. 😊